Ways to change empathy using drugs, brain stimulation, and behavior

Empathy is not a unitary phenomenon but comprises interacting yet dissociable components that rely on partially distinct neural substrates (Singer and Klimecki, 2014; Kogler et al., 2020). Affective empathy refers to the automatic sharing or resonance with another individual’s emotional state and is supported by limbic and paralimbic structures, including the anterior insula, anterior cingulate cortex, amygdala, and somatosensory cortices (Allen et al., 2017; Paradiso et al., 2021). These regions integrate interoceptive signals with externally perceived emotional cues, generating subjective feeling states that support empathic concern.

In contrast, cognitive empathy, often termed perspective-taking or mentalizing, involves inferential processes that enable individuals to represent and reason about others’ mental states. Cognitive empathy depends on prefrontal–temporal networks, particularly the right temporoparietal junction (rTPJ), the medial prefrontal cortex, the superior temporal sulcus, and the temporal poles (Chou and Chen, 2021; Jiang et al., 2022). While affective and cognitive empathy interact dynamically in real-world social behavior, they can be selectively impaired or enhanced and are differentially sensitive to intervention modalities.

This neurobiological distinction has major implications for the development of interventions. Pharmacological and neurostimulation approaches show differential effects on affective versus cognitive empathy components, and behavioral interventions often target motivational, regulatory, and cognitive processes differentially. Understanding these separations is crucial for designing selective, mechanism-informed therapeutic strategies that match intervention modality to the specific empathic deficit requiring remediation.

Alterations in empathic functioning contribute to functional impairment across a broad range of psychiatric and neurodevelopmental conditions. Autism spectrum conditions are often associated with difficulties in cognitive empathy and social reciprocity, whereas psychopathy is characterized by relatively preserved cognitive empathy alongside reduced affective empathy (Rinaldi et al., 2021). Borderline personality disorder presents with empathy dysregulation, and schizophrenia often involves mentalizing impairments alongside negative symptoms. These clinical associations have motivated interest in targeted empathy-enhancing interventions (Moudatsou et al., 2020).

Beyond psychiatric and neurodevelopmental disorders, empathy plays a central role in healthcare delivery, where higher clinician empathy is consistently associated with improved therapeutic alliance, increased patient satisfaction, better adherence, and improved outcomes (Nembhard et al., 2023; Araújo et al., 2025). Empathy-focused educational and behavioral interventions have therefore been increasingly adopted in medical and allied health training programs, with systematic reviews demonstrating moderate but reliable improvements in empathic skills (Araújo et al., 2025; Martins et al., 2025). Educational systems similarly acknowledge empathy as a fundamental social–emotional competency associated with mental health, academic engagement, and prosocial behavior (Cipriano et al., 2023). These findings have stimulated interest in scalable interventions that augment empathic capacity within both professional and general populations.

Despite extensive research activity, the science of empathy-modulation encounters ongoing methodological challenges. Most investigations depend on self-report questionnaires or brief laboratory tasks that inadequately capture the dynamic, context-dependent nature of social interactions in real-world settings (Lima and Osório, 2021). The heterogeneity of measurement approaches hampers comparability across studies and may exaggerate apparent effect sizes. Furthermore, individual differences—including genetic variation, sex, age, cultural background, and baseline empathy—contribute significant variability in responses to interventions (Chander et al., 2022; Ferguson et al., 2024).

Moreover, improvements observed in controlled experimental settings often fail to translate into sustained prosocial behavior in naturalistic environments, raising concerns about ecological validity and long-term clinical utility (Holleman et al., 2020; Winter et al., 2020). These limitations necessitate cautious interpretation of reported effects and emphasize the need for more robust translational frameworks.

This review synthesizes evidence from pharmacological, neurostimulation, and behavioral approaches pertaining to the modulation of empathy. Rather than providing prescriptive clinical guidelines, the objectives are to: (i) compile current evidence through a transparent, integrative framework; (ii) assess the magnitude, durability, and generalizability of reported effects; (iii) elucidate translational limitations and ethical considerations; and (iv) delineate priorities for future research. By contextualizing empathy modulation within its neurobiological, psychological, and sociocultural dimensions, this review endeavors to offer a balanced evaluation of current knowledge, existing uncertainties, and the prerequisites for responsible clinical application.

The present synthesis incorporates evidence from large-scale randomized trials, mechanistic neuroimaging studies, and translational safety guidelines to contextualize emerging empathy-modulation technologies (Martin et al., 2024; Murphy et al., 2025). This manuscript is a hybrid narrative–scoping review. While a structured literature search and explicit inclusion criteria are presented to enhance transparency and breadth, the primary goal is conceptual integration and translational synthesis, not exhaustive systematic review or formal evidence grading. Accordingly, established grading systems such as PRISMA or GRADE were not applied, as the intent is not to develop guidelines but to conduct critical synthesis across heterogeneous intervention modalities.

A comprehensive search was systematically conducted within PubMed, PsycINFO, Web of Science, and Scopus databases for scholarly articles published between January 2014 and March 2025. Search strategies incorporated combinations of keywords such as empathy, empathic, modulation, intervention, oxytocin, MDMA, neurostimulation, transcranial magnetic stimulation, transcranial direct current stimulation, mindfulness, compassion, and virtual reality. The reference lists of major meta-analyses, systematic reviews, and high-impact trials were meticulously screened to identify additional pertinent publications. Emphasis was placed on large-scale randomized controlled trials, registered meta-analyses and systematic reviews, studies utilizing neuroimaging techniques or established neural biomarkers, and research with explicit operational definitions of empathy constructs.

Included studies were peer-reviewed human investigations or systematic reviews that explicitly measured affective empathy, cognitive empathy, or closely related constructs such as compassion or empathic concern. Animal studies were consulted solely to contextualize neurobiological mechanisms and were not used to infer clinical effect sizes. Single-case reports, non-peer-reviewed sources, conference abstracts, and studies lacking empathy-specific outcomes were excluded.

To facilitate integrative interpretation across diverse literatures, evidence was organized using an author-defined three-tier synthesis framework, applied solely as an interpretive heuristic:

The ≥500-participant threshold for Tier 1 was selected to reduce small-study bias, enhance stability of effect-size estimates, and support cautious translational inference. This framework does not constitute formal evidence grading and is used only for synthesis and contextual guidance, not for prescriptive recommendations (Table 1).

Affective empathy involves the rapid and largely automatic sharing of another individual’s emotional state. Functional neuroimaging consistently implicates the anterior insula and anterior cingulate cortex as core hubs supporting affective resonance, emotional salience, and motivational readiness to respond to others’ distress (Singer et al., 2004; Allen et al., 2017; Rolls, 2019). The anterior insula integrates interoceptive signals with externally perceived emotional cues, generating subjective feeling states that underlie empathic concern (Craig, 2009; Allen et al., 2017). Recent neuroimaging evidence using intracranial recordings demonstrates that the insula uniquely exhibits factorized coding of emotion and agency, allowing cross-person generalization of emotional states—a computational property essential for empathic transfer (Haynes et al., 2025).

The anterior cingulate cortex contributes to the motivational and action-oriented aspects of empathy, linking emotional salience to behavioral responses through dense connectivity with limbic and reward-related structures (Rolls, 2019). The amygdala modulates threat detection and emotional learning, shaping empathic responses based on contextual relevance and prior experience (Marsh et al., 2021). Together, these regions form a limbic–paralimbic network that supports emotional contagion and empathic arousal.

Neurochemical systems modulate affective empathy within these circuits. Oxytocinergic signaling influences salience attribution and affiliative motivation by modulating amygdala–insula connectivity, while serotonergic systems regulate emotional responsiveness and affective tone (Shamay-Tsoory and Abu-Akel, 2016; Marsh et al., 2021). These mechanisms help explain why pharmacological interventions often produce context-dependent effects rather than uniform empathy enhancement.

Cognitive empathy, often operationalized as perspective-taking or theory of mind, depends on higher-order inferential processes that allow individuals to represent others’ beliefs, intentions, and emotions. The right temporoparietal junction (rTPJ) is consistently identified as a central node in this network, supporting self–other distinction and mental state attribution (Saxe and Kanwisher, 2003; Chou and Chen, 2021). Disruption of rTPJ activity using transcranial magnetic stimulation selectively alters moral judgment and reduces sensitivity to others’ intentions, providing causal evidence for its role in cognitive empathy (Chou and Chen, 2021; Jiang et al., 2022).

The medial prefrontal cortex supports integration of contextual information, trait inference, and social evaluation, while the superior temporal sulcus contributes to the processing of biological motion and socially relevant cues (Kogler et al., 2020; Tian et al., 2025; Liang et al., 2025). These regions interact dynamically during complex social reasoning tasks, enabling flexible perspective-taking.

Unlike affective empathy, cognitive empathy is less strongly linked to immediate emotional arousal and more amenable to deliberate training and cognitive strategies. This distinction helps explain why neurostimulation and behavioral interventions more reliably influence cognitive than affective components of empathy.

Empathy-related neural systems are shaped by development, experience, and sociocultural context. Longitudinal studies indicate that empathic processing undergoes protracted maturation from adolescence into older adulthood, with age-related changes in prefrontal–temporal connectivity influencing cognitive empathy capacity (Ferguson et al., 2024; Kuroda et al., 2024). Sex differences in empathic responding have been reported, with females on average showing higher affective empathy and greater limbic responsivity, though effect sizes are modest and context-dependent (Christov-Moore et al., 2014).

Genetic variation further moderates empathic responsiveness. Polymorphisms in the oxytocin receptor gene (e.g., rs53576) have been associated with individual differences in empathy and social sensitivity, though effect sizes are small and replication across populations has been inconsistent (Bakermans-Kranenburg and van IJzendoorn, 2013; Chander et al., 2022). Cultural norms and socialization practices also shape empathic expression, influencing both baseline empathy and responsiveness to interventions (Eichbaum et al., 2023; Jami et al., 2024) (Figure 1 and Table 2).

Intranasal oxytocin has been the most intensively investigated pharmacological candidate for empathy enhancement, motivated by its established role in social bonding, attachment, and affiliative behavior (Shamay-Tsoory and Abu-Akel, 2016; Matsushita and Nishiki, 2025; Yuan et al., 2025). Early small-sample studies reported increases in emotion recognition, trust, and empathic concern, generating substantial enthusiasm for oxytocin as a potential “pro-social” agent.

However, subsequent large-scale meta-analyses have substantially tempered these expectations. A comprehensive meta-analytic review encompassing more than 1,100 participants found that intranasal oxytocin produces small effects on empathy-related outcomes, with a pooled effect size of approximately d = 0.24 (95% CI: 0.02–0.46), and wide confidence intervals indicating substantial heterogeneity (Stark et al., 2023). Importantly, publication-bias–corrected estimates were markedly smaller than those reported earlier, suggesting inflated effect sizes in underpowered studies.

Oxytocin effects are highly context-dependent. Experimental work demonstrates that oxytocin can enhance empathy and cooperation toward in-group members while simultaneously increasing defensive or exclusionary responses toward perceived out-groups (Marsh et al., 2021). These findings align with the social salience hypothesis, which posits that oxytocin amplifies the perceived relevance of social cues rather than uniformly increasing prosociality (Shamay-Tsoory and Abu-Akel, 2016). Genetic moderators further complicate interpretation: polymorphisms in the oxytocin receptor gene (e.g., rs53576) have been associated with differential responsiveness, though effect sizes are small and replication across ethnic and cultural groups has been inconsistent (Bakermans-Kranenburg and van IJzendoorn, 2013; Chander et al., 2022).

Taken together, Tier 1 evidence indicates that oxytocin does not reliably produce durable or generalized empathy enhancement and is unlikely to serve as a standalone therapeutic intervention.

MDMA (3,4-methylenedioxymethamphetamine) produces robust acute empathogenic effects characterized by increased emotional openness, affiliative motivation, and perceived social connectedness (Rein et al., 2024). Unlike oxytocin, MDMA exerts its effects primarily through potent serotonin release, with secondary effects on dopamine and norepinephrine signaling, and indirect activation of oxytocinergic pathways (Vaslavski et al., 2025). A landmark 2024 study demonstrated that MDMA enhances empathy-like behaviors specifically via serotonin release in the nucleus accumbens, with direct nucleus accumbens infusion alone sufficient to reproduce systemic empathogenic effects (Rein et al., 2024).

Tier 1 evidence from large randomized controlled trials demonstrates that MDMA-assisted psychotherapy yields large effect sizes for symptom reduction in post-traumatic stress disorder, with pooled estimates approaching d ≈ 0.91 (Mitchell et al., 2021, 2023). Phase 3 clinical trials demonstrated significant reductions in PTSD symptoms, with 67–71% of participants no longer meeting diagnostic criteria compared to 32–47% in placebo groups. These effects are widely interpreted as reflecting facilitation of therapeutic engagement, emotional processing, and trust within a structured psychotherapeutic context.

Despite these promising results, MDMA’s translational scope is highly constrained. Benefits appear tightly coupled to the therapeutic setting and do not generalize to unsupervised contexts. In August 2024, the U.S. Food and Drug Administration declined approval of MDMA-assisted therapy, citing concerns related to functional unblinding, therapist expectancy effects, durability of benefit, and safety oversight (Reardon, 2024; Wolfgang et al., 2025). These concerns underscore that MDMA’s empathogenic effects, while robust, do not equate to generalized or sustained empathy enhancement and cannot currently be extrapolated to broader clinical or enhancement applications.

Classic serotonergic psychedelics, particularly psilocybin, have emerged as candidates for modulating emotional and social processing. Psilocybin primarily acts as a 5-HT2A receptor agonist, producing alterations in affective processing, self-referential cognition, and social connectedness (Jungwirth et al., 2025).

A randomized, placebo-controlled trial in patients with major depressive disorder demonstrated that psilocybin administration led to significant increases in emotional empathy, particularly toward positively valenced stimuli, with effects persisting for several weeks post-treatment (Jungwirth et al., 2025). Notably, cognitive empathy was largely unaffected, suggesting selective modulation of affective components. While these findings are promising, sample sizes remain modest, and empathy outcomes are secondary endpoints. Accordingly, psilocybin currently qualifies as Tier 2 evidence for empathy modulation.

In contrast to psychedelic-assisted interventions, conventional serotonergic antidepressants illustrate the complexity of neurochemical modulation of empathy. Contrary to assumptions that depression impairs empathy, longitudinal neuroimaging studies demonstrate that antidepressant treatment—rather than depression itself—leads to reductions in behavioral and neural responses to pain empathy. After 3 months of antidepressant therapy, patients showed significant decreases in both affective empathy and activity in brain regions associated with empathy for pain (Rütgen et al., 2019).

Clinical evidence indicates that 40–60% of individuals taking SSRI antidepressants experience “SSRI-induced indifference” or “emotional blunting,” characterized by feeling emotionally detached with reduced sympathy and empathy (Ma et al., 2021; Christensen et al., 2022). This paradoxical effect suggests that while SSRIs effectively treat depression, they may simultaneously reduce empathic responding through mechanisms affecting reinforcement learning and reward sensitivity (Langley et al., 2023). SSRIs, therefore, cannot be considered empathy-enhancing; instead, they illustrate the fragility of empathy circuits to serotonergic modulation and the importance of understanding neurochemical specificity in intervention development (Table 3).

Transcranial magnetic stimulation modulates cortical excitability through focal magnetic pulses and has been widely used to investigate the causal role of empathy-related brain regions. Meta-analytic evidence from 22 studies indicates that repetitive TMS applied to empathy-relevant cortical targets produces small but statistically significant effects on empathy-related outcomes, with pooled effect sizes around d ≈ 0.18–0.20 (Yang et al., 2018). Effects are most consistently observed for cognitive empathy, particularly when stimulating the right temporoparietal junction (rTPJ).

Experimental disruption of rTPJ activity using TMS alters moral judgment and reduces sensitivity to others’ intentions, providing causal evidence for its role in perspective-taking and mental state attribution (Chou and Chen, 2021; Jiang et al., 2022). Recent neurophysiological studies confirm that low-frequency (1 Hz) TMS over the rTPJ during empathy induction increases withdrawal of parasympathetic nervous system activity, providing enhanced evidence for the temporoparietal junction’s causal role in empathic responding (Miller et al., 2020).

Despite these insights, the translational utility of TMS remains limited. Effects typically persist for minutes to an hour post-stimulation, and repeated-session protocols have yielded inconsistent behavioral outcomes. The 2021 International Federation of Clinical Neurophysiology safety guidelines confirm the TMS safety profile with extremely rare seizure incidence (<0.1% in clinical populations), providing enhanced confidence for clinical applications (Rossi et al., 2021). However, TMS’s inability to reach deep limbic structures limits its impact on affective empathy. Given these time constraints, TMS for empathy enhancement currently serves specialized research and clinical functions rather than as a standalone therapeutic intervention.

Transcranial direct current stimulation applies weak electrical currents to modulate cortical excitability. Compared with TMS, tDCS is less spatially precise but more portable and scalable. A systematic review and meta-analysis of randomized controlled trials reported small, statistically significant effects of tDCS on empathy-related measures, with anodal stimulation over the rTPJ preferentially enhancing cognitive empathy in laboratory tasks (Bahji et al., 2021).

Contemporary research confirms that anodal tDCS over the right temporoparietal junction enhances prosocial learning by affecting cognitive empathy processes, with participants receiving active stimulation (n = 75) showing significantly improved learning performance in prosocial-learning conditions compared to self-learning contexts (Zhang et al., 2024). Clinical applications show preliminary benefits in autism spectrum disorder, where tDCS significantly improves Empathy Quotient scores and facial emotion recognition for threat-related emotions (Wilson et al., 2021). Research also investigates tDCS as an intervention to improve empathic abilities and reduce violent behavior in forensic offenders, particularly when targeting the ventromedial prefrontal cortex (Sergiou et al., 2020).

As with TMS, tDCS effects are generally transient and highly variable across individuals. Polarity-specific and montage-specific effects are difficult to reproduce consistently, limiting clinical translation (Schwertfeger et al., 2023; Son et al., 2025; Saccenti et al., 2024).

Recent technological advances have enabled noninvasive targeting of deeper brain structures implicated in empathy, though evidence remains exploratory.

Low-intensity focused ultrasound (LIFU) has emerged as a transformative non-invasive neuromodulation technique, offering millimeter-sized focal volumes with adjustable focal lengths that can target deep human brain circuitry with unprecedented precision. Unlike other non-invasive brain stimulation techniques, focused ultrasound provides focal deep brain targeting, multi-target stimulation capabilities, and neuromodulatory effects lasting from milliseconds to hours after sonication (Pellow et al., 2024; Kim et al., 2024; Martin et al., 2024). Human studies demonstrate that LIFU can modulate activity in deep structures such as the thalamus and insula, affecting pain perception and autonomic responses (Badran et al., 2020; Legon et al., 2024; Murphy et al., 2025). The European Research Council-funded HelpUS project specifically pioneers focused ultrasound as a novel non-invasive deep brain stimulation method for causal investigation of empathy-related brain processes in moral learning and decision-making (Gazzola, 2018). While these findings suggest mechanistic relevance for affective empathy, no controlled human trials have yet demonstrated direct empathy enhancement using LIFU. Accordingly, current evidence is best classified as Tier 3.

Temporal interference stimulation (TIS) represents a breakthrough non-invasive technique for steerable deep brain stimulation using multiple kHz-range electric fields with different frequencies within neural activity ranges. Human validation studies demonstrate that TIS can modulate hippocampal activity and associated cognitive effects focally, while sparing the superficial cortex (Violante et al., 2023). Open-label pilot studies show TIS targeting the right nucleus accumbens alleviates negative symptoms and improves cognitive function in schizophrenia patients, with participants demonstrating significant improvements in Positive and Negative Syndrome Scale negative subscale scores over 90 days (Wang et al., 2025). Recent safety studies involving over 250 TIS sessions confirm excellent tolerability and safety profiles (Vassiliadis et al., 2024; Modak et al., 2024). As with LIFU, TIS remains exploratory regarding empathy modulation (Figure 2 and Table 4).

Mindfulness-based interventions, including mindfulness-based stress reduction, loving-kindness meditation, and compassion meditation, are among the most extensively studied behavioral approaches to empathy enhancement. These interventions emphasize attentional regulation, interoceptive awareness, and non-reactive emotional processing, mechanisms that align closely with neural systems supporting affective regulation and empathic concern (Singer and Klimecki, 2014; Calderone et al., 2024; Abellaneda-Pérez et al., 2024).

Tier 1 meta-analytic evidence indicates that mindfulness-based programs produce small-to-moderate improvements in empathy, with a pooled effect size of approximately d = 0.37 (95% CI: 0.16–0.58), and significantly stronger effects observed in interventions exceeding 24 total hours of training (Hu et al., 2022; Bianjiang et al., 2025). However, substantial heterogeneity exists across studies, reflecting variation in program structure, instructor expertise, participant motivation, and outcome measurement. Individual participant data meta-analyses further demonstrate marked interindividual variability, with some participants showing minimal or no empathic change (Galante et al., 2023).

Neuroimaging studies provide converging mechanistic evidence, showing mindfulness-related changes in anterior insula thickness, prefrontal connectivity, and neural markers of emotional regulation (Calderone et al., 2024; Bashir et al., 2025). Nevertheless, the durability of effects depends on continued practice, and attrition rates remain a practical limitation in real-world implementation (Conversano et al., 2020; Cooper et al., 2020).

Compassion-focused therapy and related interventions explicitly train concern for others’ suffering and motivation to alleviate it. The most comprehensive recent meta-analysis of compassion-focused therapy with clinical populations found small to large effect sizes for improvements in self-compassion (0.19–0.90), self-criticism (0.15–0.72), and depression (0.24–0.25) (Millard et al., 2023; Kim et al., 2021). A 2025 systematic review found consistent improvements in self-compassion (g = 0.23–4.14) and reductions in self-criticism (g = 0.29–1.56) in clinical populations (Brown and Ashcroft, 2025; Martins et al., 2025).

Virtual reality (VR) interventions aim to enhance empathy by immersing participants in simulated social experiences. Meta-analytic evidence demonstrates that VR produces moderate short-term improvements in emotional empathy (d = 0.51, 95% CI: 0.15–0.88), while effects on cognitive empathy are inconsistent (d = 0.21, 95% CI: −0.37–0.79) (Schutte and Stilinović, 2017; Martingano et al., 2021). A systematic review found that emotional empathy increases immediately after exposure but returns to baseline levels over time (Lee et al., 2024). VR shows promise in healthcare education and stigma reduction (Tay et al., 2025; Pira et al., 2025).

Social–emotional learning (SEL) programs represent the most robust real-world applications of empathy enhancement. A contemporary meta-analysis of 424 studies from 53 countries involving 575,361 students confirmed that SEL programs improve social and emotional skills, attitudes, behavior, and academic performance (Cipriano et al., 2023; Shi and Cheung, 2024). In healthcare education, meta-analyses indicate moderate improvements in empathy following structured training (d = 0.58), with interactive approaches outperforming didactic methods (Paulus and Meinken, 2022; Araújo et al., 2025) (Table 5). Large-scale healthcare and cross-cultural reviews further confirm that empathy training improves communication quality and patient experience across diverse sociocultural contexts (Sullivan-Detheridge et al., 2024; Yuan et al., 2025).

A recent systematic review of 455 studies involving 470 analyses found that greater empathy is associated with better clinical outcomes and patient care experiences (Nembhard et al., 2023). A meta-analysis of 13 empathy training studies (N = 1,315) demonstrated an overall moderate effect size (d = 0.58) for empathy training effectiveness (Paulus and Meinken, 2022). A cluster randomized controlled trial in Ethiopian treatment centers showed sustained medium-to-large effects (d = 0.55 to 0.60) over 3 months, while simulation-based interventions showed effect sizes ranging from d = 0.46 (self-reports) to d = 1.27 (independent observers) (Chua et al., 2021; Hurissa et al., 2023).

Improved empathy among providers is associated with better diagnostic accuracy, increased medication adherence, lower malpractice risk, reduced patient anxiety and distress, and enhanced outcomes in chronic disease management. However, training effects frequently decline without reinforcement, and implementation challenges include institutional cultures that prioritize efficiency over patient interaction and systematic disparities in the quality of empathetic care for patients from lower socioeconomic backgrounds (Roberts et al., 2021; Byrne et al., 2024).

Educational systems provide a critical developmental window for cultivating empathy. Virtual patients through standardized scenarios ensure consistency and reproducibility while offering safe learning opportunities (Yamada et al., 2025). In mental health settings, empathy is foundational to the therapeutic alliance, one of the strongest predictors of treatment success. Higher therapist empathy predicts better client engagement, greater treatment adherence, and improved outcomes (Moudatsou et al., 2020). The relationship between trauma and empathy is complex, requiring tailored intervention approaches (Greenberg et al., 2018; Levy et al., 2019) (Table 6).

A central ethical challenge concerns informed consent, particularly when interventions may produce enduring changes in emotional processing or value-based decision-making. Unlike transient cognitive enhancements, empathy-related changes may persist beyond the intervention period (Winter et al., 2020). Consent processes must include explicit discussion of uncertainty regarding duration, reversibility, and downstream social consequences. Dynamic consent models—in which participants are periodically re-informed and allowed to reassess participation—have been proposed as a safeguard (Young et al., 2022).

Empathy modulation interventions are often deployed in contexts characterized by power asymmetries, including healthcare, education, military, and criminal justice settings. In such contexts, there is a risk that individuals may feel pressured to undergo interventions framed as beneficial or corrective (Sergiou et al., 2020; Beaudry et al., 2021; Roncero et al., 2025). Ethical implementation requires that participation be genuinely voluntary and that refusal carry no punitive consequences.

Contemporary research increasingly challenges deficit-based models of empathy, particularly in relation to autism spectrum conditions. The double empathy problem emphasizes that social misunderstandings arise bidirectionally between autistic and non-autistic individuals, rather than reflecting a unidirectional deficit (Cheang et al., 2025). Qualitative and quantitative studies demonstrate that autistic individuals often show intact or heightened empathy within neurodivergent peer groups (Watts et al., 2025). Ethical frameworks must respect neurodiversity and prioritize self-defined goals rather than externally imposed norms. Interventions should be co-designed with neurodivergent communities (Camilleri et al., 2025).

Empathy is expressed and valued differently across cultures, shaped by social norms, religious beliefs, and historical context. Cross-cultural research demonstrates substantial variation in empathic expression and moral priorities (Eichbaum et al., 2023; Jami et al., 2024; Sullivan-Detheridge et al., 2024). There is also concern regarding potential misuse of empathy-modulating technologies for manipulation, persuasion, or social control. International governance frameworks emphasize preventing exploitative or coercive applications (UNESCO, 2025; Ramanathan, 2025) (Table 7).